These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17186240)

  • 61. Racemic Etodolac is cytotoxic and cytostatic for B-cell precursor acute lymphoblastic leukemia cells.
    de Souza Thiago L; da Costa ES; Lopes DV; Borojevic R
    Biomed Pharmacother; 2009 Aug; 63(7):548-51. PubMed ID: 18993025
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Synergistic action of alkylating agents and methylxanthine derivatives in the treatment of chronic lymphocytic leukemia.
    Binet JL; Mentz F; Leblond V; Merle-Beral H
    Leukemia; 1995 Dec; 9(12):2159-61. PubMed ID: 8609738
    [No Abstract]   [Full Text] [Related]  

  • 63. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine.
    Hewamana S; Lin TT; Jenkins C; Burnett AK; Jordan CT; Fegan C; Brennan P; Rowntree C; Pepper C
    Clin Cancer Res; 2008 Dec; 14(24):8102-11. PubMed ID: 19088025
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Chronic lymphocytic leukaemia (CLL): clinical study at Kenyatta National Hospital (KNH).
    Oloo AJ; Ogada TA
    East Afr Med J; 1984 Nov; 61(11):797-801. PubMed ID: 6535701
    [No Abstract]   [Full Text] [Related]  

  • 65. [Clinical trial of bestrabucil (KM 2210) on hematopoietic malignancies].
    Nishikawa M; Uemura Y; Matsuoka N; Ohno T; Katayama N; Tomeoku M; Kobayashi T; Kita K; Tanaka H; Minami N
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2155-9. PubMed ID: 3521494
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin.
    Skribek H; Otvos R; Flaberg E; Nagy N; Markasz L; Eksborg S; Masszi T; Kozma A; Adam E; Miseta A; Klein E; Szekely L
    Exp Hematol; 2010 Dec; 38(12):1219-30. PubMed ID: 20837094
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Minimal change glomerulonephritis in chronic lymphocytic leukemia: pathophysiological and therapeutic aspects.
    Alzamora MG; Schmidli M; Hess U; Cathomas R; von Moos R
    Onkologie; 2006 Apr; 29(4):153-6. PubMed ID: 16601371
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Secondary cutaneous infiltration in B cell chronic lymphocytic leukemia.
    Várkonyi J; Zalatnai A; Timár J; Matolcsi A; Falus A; Bencsáth M; László V; Pócsik E; Kotlán B; Császár A
    Acta Haematol; 2000; 103(2):116-21. PubMed ID: 10838457
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The UK Medical Research Council CLL trials 1 and 2.
    Catovsky D; Fooks J; Richards S
    Nouv Rev Fr Hematol (1978); 1988; 30(5-6):423-7. PubMed ID: 3222154
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ofatumumab in previously untreated chronic lymphocytic leukaemia. No clear advantages when added to chlorambucil.
    Prescrire Int; 2015 Nov; 24(165):262. PubMed ID: 26688893
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia.
    Jensen M; Engert A; Weissinger F; Knauf W; Kimby E; Poynton C; Oliff IA; Rummel MJ; Osterborg A
    Invest New Drugs; 2008 Apr; 26(2):139-49. PubMed ID: 18094935
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A pilot study of epirubicin and chlorambucil in the treatment of chronic lymphocytic leukemia (CLL).
    Smith GM; Child JA; Milligan DW; Mcevoy MA; Murray JA
    Hematol Oncol; 1991; 9(6):315-21. PubMed ID: 1748398
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Chronic lymphocytic leukaemia and concomitant relapsing polychondritis: a report on one treatment for the combined manifestation of two diseases.
    Bochtler T; Hensel M; Lorenz HM; Ho AD; Mahlknecht U
    Rheumatology (Oxford); 2005 Sep; 44(9):1199. PubMed ID: 15855184
    [No Abstract]   [Full Text] [Related]  

  • 74. Movement toward optimization of CLL therapy.
    Rai KR; Barrientos JC
    N Engl J Med; 2014 Mar; 370(12):1160-2. PubMed ID: 24645950
    [No Abstract]   [Full Text] [Related]  

  • 75. Chronic lymphocytic leukaemia with upper airway obstruction.
    Dean MG; Cunningham I; Dao LP; Cole I; Mulligan S P
    Leuk Lymphoma; 1996 Feb; 20(5-6):505-7. PubMed ID: 8833411
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria.
    Madu AJ; Korubo K; Okoye A; Ajuba I; Duru AN; Ugwu AO; Nnachi O; Okoye HC
    Malawi Med J; 2019 Jun; 31(2):144-149. PubMed ID: 31452848
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia.
    Vitale C; Griggio V; Todaro M; Riganti C; Jones R; Boccellato E; Perutelli F; Arruga F; Vaisitti T; Efremov DG; Deaglio S; Landesman Y; Bruno B; Coscia M
    Sci Rep; 2023 Oct; 13(1):16950. PubMed ID: 37805613
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The management of acute non-lymphocytic leukaemia in adults. Evaluation of the results in a non-selected group of 114 patients.
    Dekker AW; Sixma JJ; Punt K
    Neth J Med; 1982; 25(9):297-302. PubMed ID: 7177261
    [No Abstract]   [Full Text] [Related]  

  • 79. Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia.
    Yasui H; Hideshima T; Anderson KC
    Leuk Lymphoma; 2006 Dec; 47(12):2445-6. PubMed ID: 17169789
    [No Abstract]   [Full Text] [Related]  

  • 80. Reversing of chlorambucil resistance by ethacrynic acid in a B-CLL patient.
    Petrini M; Conte A; Caracciolo F; Sabbatini A; Grassi B; Ronca G
    Br J Haematol; 1993 Oct; 85(2):409-10. PubMed ID: 8280615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.